Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 14, 2020
Daily News
February 14, 2020
- StemRIM to Set Up Collaborative Lab in Osaka University
February 14, 2020
- Mitsubishi Chemical to Rev Up Next-Gen Therapy Biz to Enliven Pharma Unit: Chief
February 14, 2020
- Polatuzumab Vedotin Hits Main Goal in Japan PII for DLBCL: Chugai
February 14, 2020
- MHLW to Weigh All-Year Invitation for Sakigake Requests: Top Pharmacy Officer
February 14, 2020
- Council Backs Public Knowledge-Based Application for Additional Indication for Novartis’ Sandostatin
February 14, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…